搜索筛选:
搜索耗时0.0908秒,为你在为你在102,285,761篇论文里面共找到 5 篇相符的论文内容
类      型:
[会议论文] 作者:Peter A Kaufman,Christopher Twelves,Javier Cortes,Ahmad Awada,Louise Yelle,Edith A Perez,Jantien Wanders, 来源:22nd Asia Pacific Cancer Conference(第22届亚太抗癌大会) 年份:2013
Objective: This phase Ⅲ study, which compared eribulin with capecitabine, showed a non-significant trend for superior overall survival ; however, no progression-free survival was noted.Pre-specified e...
[会议论文] 作者:Peter A.Kaufman,Javier Cortes,Ahmad Awada,Christopher Twelves,Louise Yelle,Edith A.Perez,Jantien Wanders, 来源:22nd Asia Pacific Cancer Conference(第22届亚太抗癌大会) 年份:2013
[会议论文] 作者:Peter A.Kaufman,Javier Cortes,Ahmad Awada,Christopher Twelves,Louise Yelle,Edith A.Perez,Jantien Wanders, 来源:22nd Asia Pacific Cancer Conference(第22届亚太抗癌大会) 年份:2013
Objective: Eribulin is a non-taxane microtubule dynamics inhibitor.In a previous phase Ⅲ trial, eribulin demonstrated a statistically significant improvement in overall survival (OS)versus current tre...
[会议论文] 作者:Peter A.Kaufman,Javier Cortes,Ahmad Awada,Christopher Twelves,Louise Yelle,Edith A.Perez,Jantien Wan, 来源:22nd Asia Pacific Cancer Conference(第22届亚太抗癌大会) 年份:2013
[会议论文] 作者:Peter A.Kaufman,Javier Cortes,Ahmad Awada,Christopher Twelves,Louise Yelle,Edith A.Perez,Jantien Wan, 来源:22nd Asia Pacific Cancer Conference(第22届亚太抗癌大会) 年份:2013
Objective: Eribulin is a non-taxane microtubule dynamics inhibitor.In a previous phase Ⅲll trial, eribulin demonstrated a statistically significant improvement in overall survival (OS)versus current t...
相关搜索: